Indrayani Biotech Ltd
Incorporated in 1992, Indrayani Biotech
Ltd is in the business of Foods & Hospitality, Engineering and Healthcare[1]
- Market Cap ₹ 37.4 Cr.
- Current Price ₹ 8.22
- High / Low ₹ 27.5 / 7.99
- Stock P/E
- Book Value ₹ 16.6
- Dividend Yield 0.00 %
- ROCE -1.12 %
- ROE -8.75 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.49 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 33.3%
- Company has a low return on equity of 5.79% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.5.64 Cr.
- Company has high debtors of 164 days.
- Promoter holding has decreased over last 3 years: -11.6%
- Working capital days have increased from 114 days to 211 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 39 | 58 | 50 | 21 | 61 | 163 | 165 | 130 | 133 | |
| 0 | 39 | 57 | 47 | 26 | 54 | 145 | 142 | 115 | 128 | |
| Operating Profit | -0 | 1 | 1 | 3 | -5 | 7 | 17 | 24 | 15 | 5 |
| OPM % | -105% | 2% | 1% | 6% | -24% | 11% | 11% | 14% | 12% | 4% |
| 0 | 0 | 0 | 0 | -4 | 0 | 4 | 1 | 3 | 6 | |
| Interest | 0 | 0 | 0 | 1 | 2 | 2 | 6 | 10 | 3 | 3 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 4 | 21 | 14 |
| Profit before tax | -0 | 0 | 0 | 1 | -11 | 4 | 12 | 11 | -6 | -7 |
| Tax % | 0% | 150% | 300% | 0% | 0% | 0% | 3% | 5% | 6% | |
| -0 | -0 | -0 | 1 | -11 | 4 | 12 | 10 | -6 | -7 | |
| EPS in Rs | -0.14 | -0.16 | 2.22 | -3.28 | 1.30 | 2.55 | 1.40 | -1.34 | -1.58 | |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 29% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -204% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -1% |
| 3 Years: | -53% |
| 1 Year: | -70% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 6% |
| Last Year: | -9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 4 | 4 | 4 | 34 | 34 | 34 | 46 | 46 | 46 |
| Reserves | -6 | -0 | -0 | 27 | -15 | -10 | 12 | 22 | 27 | 30 |
| 0 | 0 | 0 | 14 | 16 | 19 | 79 | 113 | 137 | 146 | |
| 1 | 6 | 9 | 7 | 5 | 8 | 31 | 54 | 59 | 52 | |
| Total Liabilities | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 | 274 |
| 1 | 6 | 6 | 17 | 15 | 17 | 57 | 62 | 58 | 62 | |
| CWIP | -0 | 0 | 0 | 14 | 14 | 13 | 14 | 20 | 26 | 23 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 4 | 7 | 21 | 11 | 22 | 85 | 151 | 185 | 189 | |
| Total Assets | 1 | 10 | 12 | 51 | 40 | 51 | 156 | 234 | 268 | 274 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 6 | 0 | 4 | 16 | -30 | -7 | ||
| -3 | -0 | -4 | -1 | -1 | -47 | -16 | 25 | ||
| 2 | -1 | -1 | -0 | -3 | 33 | 44 | -18 | ||
| Net Cash Flow | 0 | 1 | 1 | -1 | 1 | 2 | -2 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2010 | Mar 2011 | Mar 2012 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 26 | 26 | 52 | 84 | 84 | 67 | 87 | 164 |
| Inventory Days | 365 | 57 | 25 | 14 | 44 | 159 | 146 | ||
| Days Payable | 365 | 70 | 77 | 52 | 81 | 141 | 83 | ||
| Cash Conversion Cycle | 0 | 26 | 26 | 38 | 32 | 46 | 30 | 106 | 227 |
| Working Capital Days | -1,883 | -22 | -19 | 30 | -59 | -12 | 6 | 127 | 211 |
| ROCE % | 28% | 12% | -13% | 16% | 23% | 14% | -1% |
Documents
Announcements
-
Defaults under Para A sub-paragraph 6 of Schedule III-Initial Disclosure
31 Jan - SARFAESI notice 30-01-2026: NPA classification; borrower outstanding Rs6.46Cr; total debt Rs54.48Cr.
-
Defaults under Para A sub-paragraph 6 of Schedule III-Initial Disclosure
31 Jan - SARFAESI notice (30/01/2026): loans NPA; borrower Rs6.46 crore, co-borrower Rs19.12 crore.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Jan - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December 2025
- Closure of Trading Window 26 Dec 2025
-
Results For Unaudited Fnancial Results For Quarter And Half Year Ended September 2025
19 Dec 2025 - Approved unaudited results for quarter/half ended Sep 30, 2025; director resigned Nov 13, 2025; BSE fine paid.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
IBL has multiple business units managed by an
independent team of field experts. It operates
in Food and Hospitality, Dairy, Healthcare & Pharma, Engineering, Biotech, Agriculture and Infrastructure